Cosmetic cross-reference

Oridonin

CAS 28957-04-2

Oridonin (CAS 28957-04-2) is a pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
5
SOURCE DrugCentral
Adverse signals
0
SOURCE IUPHAR/BPS
PubMed IDs
3
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Oridonin
CAS Number
28957-04-2
UNII
0APJ98UCLQ
InChIKey
SDHTXBWLVGWJFT-XKCURVIJSA-N
ChEMBL ID
CHEMBL1164920
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
natural product
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 5 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- IC50 15363.971046511628 nM 171 -
- EC50 14421.07142857143 nM 28 -
- MIC 48 ug.mL-1 3 -
- GI50 453 nM 1 -
- IC50 4 ug.mL-1 1 -
SOURCE IUPHAR/BPS 4 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
AKT serine/threonine kinase 1
AKT1
Inhibition 5.079999923706055 pIC50 29695636
AKT serine/threonine kinase 2
AKT2
Inhibition 5.050000190734863 pIC50 29695636
BB 3 receptor
BRS3
Agonist 6.619999885559082 pEC50 35405616
NLRP3
NLRP3
Inhibition 7.28000020980835 pKd 29959312
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Oridonin used for in pharmaceutical contexts?

Oridonin (CAS 28957-04-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Oridonin?

No adverse-event association or SIDER side-effect rows are rendered for Oridonin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Oridonin also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for ORIDONIN with EU status "permitted".

What clinical phase is Oridonin in?

No phase 1-4 clinical development badge is rendered for Oridonin because the matched compound identifier rows do not contain a max-phase value.